Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$9.2b

Bio-Rad Laboratories Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIO ($328.36) is trading above our estimate of fair value ($327.4)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Key metric: As BIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIO. This is calculated by dividing BIO's market cap by their current revenue.
What is BIO's PS Ratio?
PS Ratio3.6x
SalesUS$2.58b
Market CapUS$9.16b

Price to Sales Ratio vs Peers

How does BIO's PS Ratio compare to its peers?

The above table shows the PS ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.5x
QGEN Qiagen
5.1x7.3%US$9.9b
RGEN Repligen
12.9x12.9%US$8.1b
CRL Charles River Laboratories International
2.3x4.4%US$9.5b
TECH Bio-Techne
9.9x8.8%US$11.6b
BIO Bio-Rad Laboratories
3.6x3.6%US$9.2b

Price-To-Sales vs Peers: BIO is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (7.5x).

Price to Sales Ratio vs Industry

How does BIO's PS Ratio compare vs other companies in the US Life Sciences Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.73b
ATLN Atlantic International
0.5xn/aUS$256.75m
NOTV Inotiv
0.2x6.0%US$106.14m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
BIO 3.6xIndustry Avg. 3.4xNo. of Companies9PS02.85.68.411.214+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BIO is expensive based on its Price-To-Sales Ratio (3.6x) compared to the US Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is BIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.6x
Fair PS Ratio4x

Price-To-Sales vs Fair Ratio: BIO is good value based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$328.36
US$404.33
+23.1%
13.8%US$481.00US$315.00n/a6
Dec ’25US$340.53
US$402.33
+18.1%
13.3%US$469.00US$315.00n/a6
Nov ’25US$368.42
US$399.00
+8.3%
14.1%US$469.00US$315.00n/a6
Oct ’25US$337.69
US$388.50
+15.0%
12.0%US$446.00US$315.00n/a6
Sep ’25US$337.32
US$372.67
+10.5%
10.8%US$430.00US$315.00n/a6
Aug ’25US$341.25
US$366.40
+7.4%
13.8%US$430.00US$300.00n/a5
Jul ’25US$263.97
US$366.40
+38.8%
13.8%US$430.00US$300.00n/a5
Jun ’25US$286.86
US$393.80
+37.3%
12.8%US$440.00US$300.00n/a5
May ’25US$274.06
US$419.90
+53.2%
6.2%US$441.00US$365.00n/a6
Apr ’25US$338.98
US$435.73
+28.5%
5.6%US$480.00US$400.00n/a6
Mar ’25US$332.30
US$435.73
+31.1%
5.6%US$480.00US$400.00n/a6
Feb ’25US$328.96
US$432.60
+31.5%
6.8%US$484.00US$395.00n/a6
Jan ’25US$322.89
US$436.67
+35.2%
7.2%US$484.00US$395.00n/a6
Dec ’24US$307.00
US$444.60
+44.8%
6.1%US$482.00US$400.00US$340.535
Nov ’24US$277.50
US$444.60
+60.2%
6.1%US$482.00US$400.00US$368.425
Oct ’24US$358.45
US$530.25
+47.9%
3.4%US$560.00US$511.00US$337.694
Sep ’24US$394.60
US$534.20
+35.4%
3.4%US$560.00US$511.00US$337.325
Aug ’24US$407.31
US$556.40
+36.6%
5.8%US$605.00US$522.00US$341.255
Jul ’24US$379.12
US$559.20
+47.5%
5.3%US$605.00US$525.00US$263.975
Jun ’24US$371.36
US$561.50
+51.2%
5.8%US$605.00US$525.00US$286.864
May ’24US$453.91
US$606.75
+33.7%
7.9%US$680.00US$550.00US$274.064
Apr ’24US$479.02
US$606.00
+26.5%
8.0%US$680.00US$550.00US$338.984
Mar ’24US$475.41
US$606.00
+27.5%
8.0%US$680.00US$550.00US$332.304
Feb ’24US$473.42
US$590.25
+24.7%
5.7%US$640.00US$550.00US$328.964
Jan ’24US$420.49
US$588.75
+40.0%
5.9%US$640.00US$550.00US$322.894
Dec ’23US$418.04
US$596.67
+42.7%
6.2%US$640.00US$550.00US$307.003

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:43
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Sel HardyCFRA Equity Research